#United States #La Jolla #ARPA-H #InflammaSense #VITALx-patch

InflammaSense Secures Major Funding for Immune Monitoring in Critical Care

In a significant development for the medtech industry, InflammaSense, Inc. has been chosen as a performer under an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program, potentially receiving up to $38 million. This funding is aimed at evolving the methodologies by which healthcare professionals monitor and treat patients suffering from critical illnesses, particularly in intensive care units.

Transforming Critical Care through Technology

The CIRCLE program—which stands for Critical Illness Immunological Reprogramming and Control Point Learning Engine—focuses on addressing the immune dysregulation that frequently leads to organ failure in critically ill patients. Sepsis, a severe reaction to infection, currently affects around 4.6 million people in the U.S. annually, often resulting in catastrophic health outcomes.

The CIRCLE initiative represents a comprehensive approach that follows a measure-model-modulate framework. This strategic process entails gathering real-time datasets on immune and inflammatory trajectories, constructing patient-specific computational models, and executing interventions that target key immune control points before the onset of organ failure, thereby improving patient outcomes.

InflammaSense's Role in the CIRCLE Program

As part of this initiative, InflammaSense will introduce its VITALx-patch, a cutting-edge non-invasive wearable sensor designed to monitor autonomic and inflammatory signatures in up to 200 critically ill patients across three different clinical sites. The data obtained will integrate into the company's Autonomic Research Core (ARC), which utilizes a cascade-endotyping classifier to segment patients based on their immune trajectories. This collaboration not only reinforces InflammaSense's standing in the medtech space but also contributes to a groundbreaking digital-twin modeling of critical illnesses, providing essential insights for healthcare providers.

The Science Behind the Technology

The foundation of InflammaSense's work rests on advanced research from the University of California, San Diego. The wearable sensor technology focuses on neural signal detection of immune responses via cervical Autonomic Neurography (ANG), employing techniques such as ventral cervical magnetoneurography and electroneurography. These sophisticated methods enable real-time monitoring of the autonomic nervous system, which is vital in understanding complex inflammatory responses in critically ill patients.

“The CIRCLE program gives us a path to validate ANG at scale in the population it was designed to serve,” remarked Imanuel Lerman, MD, MSc, CEO and Founder of InflammaSense. “Detecting states of sepsis hyperimmune or immunoparalysis is notoriously challenging with current tools; this program aims to discern whether continuous, non-invasive ANG monitoring can effectively signal critical changes early enough for timely intervention.”

The Road Ahead

This funding not only symbolizes a vote of confidence in InflammaSense’s innovative approach but also highlights the ongoing evolution in critical care monitoring technology. As the landscape of healthcare continuously shifts towards personalization and data-driven decision-making, projects like CIRCLE represent a pivotal step forward in improving patient outcomes and redefining treatment protocols for critical illnesses.

With the healthcare industry increasingly leaning on tech advancements to manage complex conditions, InflammaSense is poised to make significant contributions to real-time immune monitoring and clinical care. The advancements made through the CIRCLE program may set a new standard for how healthcare providers respond to life-threatening conditions, ultimately benefiting countless patients in critical care settings.